Julia Escandon Stephanie Peacock Asaad Trabolsi David B Thomas Ayman Layka Jose Lutzky
10.1186/s40425-016-0205-2
J Immunother Cancer
2017 Jan 17;5:3.
immune checkpoint inhibitor interstitial nephritis nivolumab pd-1 ligand (pd-l1) pembrolizumab programed death 1 receptor (pd-1)
CC BY
https://pubmed.ncbi.nlm.nih.gov/28105370/
Inflammation / drug therapy Melanoma / drug therapy Nephritis, Interstitial / drug therapy Programmed Cell Death 1 Receptor / immunology
Inflammation / drug therapy Melanoma / drug therapy Nephritis, Interstitial / drug therapy Programmed Cell Death 1 Receptor / immunology Case Reports Aged Antibodies, Monoclonal / administration & dosage Antibodies, Monoclonal / adverse effects Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Combined Chemotherapy Protocols / administration & dosage Antineoplastic Combined Chemotherapy Protocols / adverse effects Drug-Related Side Effects and Adverse Reactions / immunology Drug-Related Side Effects and Adverse Reactions / pathology Female Humans Immunotherapy Inflammation / immunology Inflammation / pathology Ipilimumab / administration & dosage Ipilimumab / adverse effects Male Melanoma / immunology Melanoma / pathology Middle Aged Neoplasm Metastasis Nephritis, Interstitial / immunology Nephritis, Interstitial / pathology Nivolumab Programmed Cell Death 1 Receptor / antagonists & inhibitors Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Ipilimumab PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab pembrolizumab
PMC5240303
28105370
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
2017